ReviewJournal of medical case reports2026
Osimertinib-induced acute decompensated heart failure: a case report and review of the literature.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC), which is one of the most common cancer types, has caused lots of deaths to patients worldwide. Aside from the surgical treatment or chemotherapy, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), Osimertinib, is used as a treatment for patients with non-small cell lung cancer. However, the cardiotoxicity related to Osimertinib, which is rarely reported, is still a controversial issue to be discussed. CASE PRESENTATION: A 70-year-old Taiwanese female diagnosed with lung adenocarcinoma had been with Osimertinib treatment for two years. During admission for a routine lung cancer staging workup, she developed acute-onset dyspnea with pulmonary edema. She did not present with any infection-related symptoms. The echocardiography revealed global hypokinesis, while a thallium scan showed no evidence of myocardial infarction. Her symptoms resolved gradually following the withdraw of Osimertinib.
conclusionWe report a case of acute decompensated heart failure in a patient with lung cancer who had been receiving Osimertinib therapy for two years. To the best of our knowledge, this represents the longest the interval reported between initiation of Osimertinib and the onset of cardiotoxicity. The diagnosis of Osimertinib-related heart failure was made by exclusion of the other etiologies, and the patient's clinical symptoms recovered after cessation of Osimertinib for one week. Although the cause of Osimertinib-related cardiotoxicity is still unclear, regular cardiac examination of the patients should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.